COMMUNIQUÉS West-GlobeNewswire

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
01/10/2024
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty [...]
TerrAscend Closes on Remaining US$26 Million Draw of US$140 Million Debt Financing
01/10/2024
Proceeds from second draw used to pay down higher interest Michigan debt TORONTO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North American [...]
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
01/10/2024
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
01/10/2024
This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic goal of sustaining a generic powerhouse . O ctreotide acetate for injectable suspension is [...]
AMN Healthcare Announces CFO Transition
01/10/2024
Jeffrey Knudson to Step Down as CFO Following Company’s Q3 Report Company Expects to Announce New Leader in Expanded CFO/COO Role Prior to November 8 Reaffirms Third Quarter 2024 Outlook DALLAS, Oct. 01, 2024 (GLOBE [...]
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
01/10/2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30/09/2024
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 120,000 shares of [...]
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
30/09/2024
TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on [...]
Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
30/09/2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies [...]
Precision Optics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
30/09/2024
Conference Call Scheduled for today, September 30, 2024, at 5:00pm ET. GARDNER, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of [...]
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
30/09/2024
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator — — The [...]
Biocodex Microbiota Foundation Invites Canadian Academics and Scientists to Apply for €25,000 Research Grant to Advance Microbiota’s role Study in health and diseases
30/09/2024
MONTREAL, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant [...]
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
30/09/2024
Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise monitoring of low- [...]
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
30/09/2024
2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better [...]
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
30/09/2024
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk [...]
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
30/09/2024
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative [...]
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
30/09/2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at [...]
The Pennant Group Announces Public Offering of Common Stock
30/09/2024
EAGLE, Idaho, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG) (the “Company”) today announced that it has commenced an underwritten public offering of 3,500,000 shares of common stock of the [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
30/09/2024
WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]

Pages